FDA Refuses Review of Moderna’s mRNA Flu Vaccine
- February 13, 2026
Moderna, Inc. reported this week that the Food and Drug Administration (FDA) has refused to review its biologics license application for its investigational influenza vaccine using the same mRNA technology as its COVID-19 shot.
ARTICLE TAGS
You must be logged in to access this content.